12:13 PM EST - Crescita Therapeutics Inc. : Announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene , which is known to work on Cannabidiol’s two receptors. Crescita Therapeutics Inc.
shares T.CTX are trading up $0.02 at $0.55.
